Disclosed is a method to identify compounds useful for reducing insulin
resistance in a patient, and particularly a patient that has insulin
resistance associated with obesity and/or type II diabetes. Also disclosed
is a method of reducing insulin resistance in a patient by administering a
compound identified using the method of the invention, and particularly,
by administering an antagonist of melanocortin stimulating hormone (MSH)
biological activity.
